Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) closed the day trading at $15.77 down -5.79% from the previous closing price of $16.74. In other words, the price has decreased by -$5.79 from its previous closing price. On the day, 1.1 million shares were traded. ARQT stock price reached its highest trading level at $16.7512 during the session, while it also had its lowest trading level at $15.735.
Ratios:
For a better understanding of ARQT, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.04 and its Current Ratio is at 3.20. In the meantime, Its Debt-to-Equity ratio is 0.79 whereas as Long-Term Debt/Eq ratio is at 0.79.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on July 25, 2025, initiated with a Neutral rating and assigned the stock a target price of $18.
On December 30, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $19.
On August 28, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $15.Jefferies initiated its Buy rating on August 28, 2024, with a $15 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 19 ’25 when Burnett Patrick bought 1,750 shares for $16.13 per share.
Burnett Patrick sold 3,847 shares of ARQT for $53,988 on Aug 08 ’25. The insider now owns 108,999 shares after completing the transaction at $14.03 per share. On Aug 08 ’25, another insider, Topper David Joseph, who serves as the Former Officer of the company, bought 41,979 shares for $14.58 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARQT now has a Market Capitalization of 1890901888 and an Enterprise Value of 1810243072. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.18 while its Price-to-Book (P/B) ratio in mrq is 13.59. Its current Enterprise Value per Revenue stands at 6.871 whereas that against EBITDA is -22.608.
Stock Price History:
The Beta on a monthly basis for ARQT is 1.94, which has changed by 0.89088726 over the last 52 weeks, in comparison to a change of 0.14064062 over the same period for the S&P500. Over the past 52 weeks, ARQT has reached a high of $17.75, while it has fallen to a 52-week low of $8.03. The 50-Day Moving Average of the stock is 8.13%, while the 200-Day Moving Average is calculated to be 15.05%.
Shares Statistics:
Over the past 3-months, ARQT traded about 1.86M shares per day on average, while over the past 10 days, ARQT traded about 2217000 shares per day. A total of 119.80M shares are outstanding, with a floating share count of 104.50M. Insiders hold about 12.85% of the company’s shares, while institutions hold 98.75% stake in the company. Shares short for ARQT as of 1753920000 were 16637743 with a Short Ratio of 8.93, compared to 1751241600 on 20595825. Therefore, it implies a Short% of Shares Outstanding of 16637743 and a Short% of Float of 17.14.
Earnings Estimates
Current recommendations for the stock of the company come from 5.0 analysts. The consensus estimate for the next quarter is -$0.02, with high estimates of $0.03 and low estimates of -$0.06.
Analysts are recommending an EPS of between -$0.35 and -$0.52 for the fiscal current year, implying an average EPS of -$0.46. EPS for the following year is $0.13, with 6.0 analysts recommending between $0.4 and -$0.21.
Revenue Estimates
6 analysts predict $86.69M in revenue for the current quarter. It ranges from a high estimate of $92M to a low estimate of $83.5M. As of the current estimate, Arcutis Biotherapeutics Inc’s year-ago sales were $44.76MFor the next quarter, 6 analysts are estimating revenue of $98.27M. There is a high estimate of $107.7M for the next quarter, whereas the lowest estimate is $92.28M.
A total of 8 analysts have provided revenue estimates for ARQT’s current fiscal year. The highest revenue estimate was $347M, while the lowest revenue estimate was $323.13M, resulting in an average revenue estimate of $332.31M. In the same quarter a year ago, actual revenue was $196.54MBased on 8 analysts’ estimates, the company’s revenue will be $437.63M in the next fiscal year. The high estimate is $468.4M and the low estimate is $418.84M.
